Starpharma Holdings

Activities: Drug Delivery Research & Development Pharmaceutical

Trending Articles

  1. LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
  2. Fasenra for EGPA: addressing unmet needs Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  4. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
  5. Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

Related Content

Drug Delivery

Starpharma signs drug delivery licence with AstraZeneca

AstraZeneca to use of DEP drug delivery platform in the development and commercialisation of an oncology compound with potential for follow on compounds directed at a defined family of targets
Research & Development

Starpharma and Monash University receive funding

Dendrimer drug delivery method could benefit cancer and HIV patients
Drug Delivery

Starpharma and Lilly agree drug delivery collaboration

Starpharma Holdings of Melbourne, Australia, has signed a new agreement with Eli Lilly, which will use Starpharma\'s dendrimer drug delivery technology in its human pharmaceutical product line.
Subscribe now